News & Updates

Daily use of somatropin, a recombinant human growth hormone (rhGH), led to significantly improved growth outcomes, particularly height standard deviation scores (HT-SDSs), in prepubertal children with idiopathic short stature (ISS), according to a recent study.

One year after undergoing percutaneous coronary intervention (PCI), high-risk patients on clopidogrel monotherapy have a reduced risk of multiple cardiovascular (CV) outcomes compared with those on aspirin monotherapy, according to a study presented at SCAI 2022.

In the first-line treatment of locally advanced or metastatic esophageal squamous cell carcinoma (ESCC), adding the anti-PD-1 monoclonal antibody toripalimab to a standard chemotherapy regimen can significantly cut the risk of progression or death without an increase in adverse events, according to the prespecified analysis of the phase III JUPITER-06 trial.

Treatment with a nonhallucinogenic phytocannabinoid, cannabidivarin, is well tolerated in children with Rett syndrome (RTT), according to data from a phase 1 trial. Moreover, it improves seizure control in those whose disease is caused by methyl-CpG-binding protein 2 (MECP2) pathogenic variants.

Patients with major depressive disorder (MDD) generally achieve satisfactory treatment response with antipsychotic treatment, used either as monotherapy or adjunctively, a meta-analysis has shown. However, this benefit comes with an increased risk of adverse events.